Whalesbook
Zaynich Ab Approval Ke Kareeb Hai India Mein
Toh hua kya hai, ki Wockhardt ki ekdum nayi antibiotic, jiska naam hai Zaynich (zidebactam aur cefepime ka combo), usko India ki CDSCO (Central Drugs Standard Control Organisation) ke expert panel ne final approval ke liye aage badha diya hai. Ab bas DCGI (Drugs Controller General of India) ki final stamp lagni baaki hai. Yeh drug 15 saal se zyada time lekar banayi gayi hai aur isne global Phase 3 trials mein complicated urinary tract infections ke liye purane drug meropenem se better results dikhaye hain. Iska main target multi-drug resistant gram-negative bacteria hain, jo aajkal badi problem ban gayi hai.
Stock Ka Kya Scene Hai?
Par interesting baat yeh hai ki, itni acchi khabar aane ke baad bhi Wockhardt ka stock pressure mein hai. March 2026 end tak yeh lagbhag ₹1,189.50 ke aas-paas trade kar raha tha. Saal mein 15% se zyada aur pichhle saal mein 16% tak gira hai, haalanki 3 saal mein 545.29% ka tagda return diya hai. Company ka market cap ₹19,300 crore ke aas-paas hai. Shayad investors ko iski profitability ko lekar kuch chinta hai ya fir nayi antibiotics develop karne ka kharcha bahut zyada hai.
Company Ka Strategy Shift
Ab sabse important strategy shift yeh hai ki Wockhardt apna loss-making US generics business band kar rahi hai. Woh apni US subsidiaries, Morton Grove Pharmaceuticals Inc. aur Wockhardt USA LLC, ko voluntary liquidate kar rahe hain, jismein fiscal year 2025 mein lagbhag $8 million ka loss hua tha. Yeh paisa ab innovation mein lagaya jayega, especially nayi antibiotics aur biologics (like insulin) development mein. Company ka kehna hai ki woh nayi antibiotics development mein global leader hain aur unke paas 6 nayi drugs ka pipeline hai. USFDA se 6 anti-bacterial programs ke liye QIDP status bhi mila hua hai. Wockhardt ne apne antibiotic portfolio mein lagbhag $700-800 million invest kiye hain.
Global Market Aur Competitors
Duniya bhar mein antibiotics market $45.6 billion (2023) se badhkar 2032 tak $60 billion se zyada hone ka estimate hai, kyunki antimicrobial resistance (AMR) badh rahi hai. Lekin is field mein R&D karna mushkil hai, kyunki bade pharma companies isse cancer jaise chronic diseases ke treatment se kam profitable maanti hain. Wockhardt cost-effective innovation par focus kar raha hai, aur competitors mein Pfizer, GlaxoSmithKline, aur Merck jaise bade naam hain. Wockhardt ka target asli molecules develop karke licensing deals se expand karna hai.
Challenges Toh Hain Yaar
Lekin Zaynich ke promise ke bawajood, Wockhardt ko financial challenges face karne pad rahe hain. Company ka P/E ratio kaafi volatile raha hai, aur kai saalon se negative ROE (around -0.53%) dikha raha hai. ROCE bhi low hai, lagbhag 3.75%. MarketsMojo ne toh ise "Strong Sell" rating di hai, jismein bolte hain ki quality kamzor hai aur sales growth bhi slow (past 5 years mein 2.66%). Analyst ke views alag hain; ek broker ne ₹1,870 target price ke saath "BUY" recommend kiya hai. Company ka P/B ratio 4 ke aas-paas hai, jo valuation ko expensive bana sakta hai.
Future Kya Kehta Hai?
Ab sabki nazar US aur EU mein approval timeline par rahegi, aur Wockhardt is drug se kaise profit kamayega. Company ka future, Zaynich jaise innovation ko successfully commercialize karne par depend karta hai. Yeh move long-term vision dikhata hai, par Wockhardt ko global pharma challenges, consistent profit, aur investor confidence phir se jeetna hoga. Promoter holding kam hui hai aur company dividend bhi nahi deti, jo income investors ke liye achha sign nahi hai.